Literature DB >> 33635184

Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants.

Shan Su1, Yiming Shao2, Shibo Jiang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33635184      PMCID： PMC7971202          DOI： 10.1080/22221751.2021.1896956

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN： 2222-1751            Impact factor:   7.163


× No keyword cloud information.
  6 in total

1.  Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development.

Authors:  Jeffrey P Kahn; Leslie Meltzer Henry; Anna C Mastroianni; Wilbur H Chen; Ruth Macklin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-29       Impact factor: 11.205

2.  Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models.

Authors:  Meagan E Deming; Nelson L Michael; Merlin Robb; Myron S Cohen; Kathleen M Neuzil
Journal:  N Engl J Med       Date:  2020-07-01       Impact factor: 91.245

3.  Estimates of the severity of coronavirus disease 2019: a model-based analysis.

Authors:  Robert Verity; Lucy C Okell; Ilaria Dorigatti; Peter Winskill; Charles Whittaker; Natsuko Imai; Gina Cuomo-Dannenburg; Hayley Thompson; Patrick G T Walker; Han Fu; Amy Dighe; Jamie T Griffin; Marc Baguelin; Sangeeta Bhatia; Adhiratha Boonyasiri; Anne Cori; Zulma Cucunubá; Rich FitzJohn; Katy Gaythorpe; Will Green; Arran Hamlet; Wes Hinsley; Daniel Laydon; Gemma Nedjati-Gilani; Steven Riley; Sabine van Elsland; Erik Volz; Haowei Wang; Yuanrong Wang; Xiaoyue Xi; Christl A Donnelly; Azra C Ghani; Neil M Ferguson
Journal:  Lancet Infect Dis       Date:  2020-03-30       Impact factor: 25.071

4.  SARS-CoV-2 evolution during treatment of chronic infection.

Authors:  Steven A Kemp; Dami A Collier; Rawlings P Datir; Isabella A T M Ferreira; Salma Gayed; Aminu Jahun; Myra Hosmillo; Chloe Rees-Spear; Petra Mlcochova; Ines Ushiro Lumb; David J Roberts; Anita Chandra; Nigel Temperton; Katherine Sharrocks; Elizabeth Blane; Yorgo Modis; Kendra E Leigh; John A G Briggs; Marit J van Gils; Kenneth G C Smith; John R Bradley; Chris Smith; Rainer Doffinger; Lourdes Ceron-Gutierrez; Gabriela Barcenas-Morales; David D Pollock; Richard A Goldstein; Anna Smielewska; Jordan P Skittrall; Theodore Gouliouris; Ian G Goodfellow; Effrossyni Gkrania-Klotsas; Christopher J R Illingworth; Laura E McCoy; Ravindra K Gupta
Journal:  Nature       Date:  2021-02-05       Impact factor: 69.504

5.  Extraordinary diseases require extraordinary solutions.

Authors:  Stanley A Plotkin; Arthur Caplan
Journal:  Vaccine       Date:  2020-04-20       Impact factor: 3.641

6.  Development of an inactivated vaccine candidate for SARS-CoV-2.

Authors:  Qiang Gao; Linlin Bao; Haiyan Mao; Lin Wang; Kangwei Xu; Minnan Yang; Yajing Li; Ling Zhu; Nan Wang; Zhe Lv; Hong Gao; Xiaoqin Ge; Biao Kan; Yaling Hu; Jiangning Liu; Fang Cai; Deyu Jiang; Yanhui Yin; Chengfeng Qin; Jing Li; Xuejie Gong; Xiuyu Lou; Wen Shi; Dongdong Wu; Hengming Zhang; Lang Zhu; Wei Deng; Yurong Li; Jinxing Lu; Changgui Li; Xiangxi Wang; Weidong Yin; Yanjun Zhang; Chuan Qin
Journal:  Science       Date:  2020-05-06       Impact factor: 47.728
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.